Evidence map›Paper›PMID 41048932›Full record

ArticleFrontiers in medicine2025

Incidence, risk factors and evolving treatment of severe retinopathy of prematurity in China: a retrospective multicenter cohort study in 70 neonatal intensive care units.

Xuting Chen, Yu Xu, Yanchen Wang, Juan Du, Falin Xu, Xinyue Gu, Yun Cao, Jianhua Sun, Mingyan Hei, Shoo Lee and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuting Chen *Department of Neonatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu Xu *Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanchen WangNHC Key Laboratory of Neonatal Diseases (Fudan University), Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Juan DuNeonatal Center, Beijing Children's Hospital, Capital Medical University, National Children's Medical Center, Beijing, China.
Falin XuDepartment of Neonatology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinyue GuNHC Key Laboratory of Neonatal Diseases (Fudan University), Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Yun CaoDepartment of Neonatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Jianhua SunDepartment of Neonatology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mingyan HeiNeonatal Center, Beijing Children's Hospital, Capital Medical University, National Children's Medical Center, Beijing, China.
Shoo LeeMaternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, ON, Canada.
Hongping XiaDepartment of Neonatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chinese Neonatal Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the current incidence, risk factors and treatment for severe retinopathy of prematurity (ROP) in very preterm infants in China. Methods: This was a descriptive, retrospective cohort study. The study population was very preterm infants admitted to one of the 70 neonatal intensive care units (NICUs) in the Chinese Neonatal Network who underwent ROP screening between January 2019 and December 2020. The primary outcome was severe ROP, defined as type 1 or type 2 ROP. Potential risk factors were identified based on prior evidence and statistical significance. Adjusted odds ratios with 95% confidence intervals were calculated using a multivariable multinomial logistic regression model. Results: This study included 14,670 very preterm infants, among which 17.3% had low-grade ROP, and 8.5% had severe ROP. Treatment was performed in 1,381 (4.7%) eyes of the infants, among which 1,029 (74.5%), 148 (10.7%), and 124 (9.0%) received intravitreal anti-vascular endothelial growth factor injection only, laser treatment only, and vitreoretinal surgery, respectively. Extremely preterm birth (7.61, 95% CI: 6.12-9.46), small for gestational age (SGA; 2.31, 95% CI: 1.71-3.12), outborn status (1.43, 95% CI: 1.22-1.67), 1-min Apgar score < 7 (1.30, 95% CI: 1.11-1.51), >40 days on oxygen (1.70, 95% CI: 1.37-2.10), >28 days on parenteral nutrition (PN; 1.17, 95% CI: 1-1.35), and any inotropes use (2.12, 95% CI: 1.82-2.46) were associated with increased odds of severe ROP. Antenatal steroid use (0.77, 95% CI: 0.66-0.91), large for gestational age (LGA; 0.62, 95% CI: 0.45-0.85), and surfactant treatment (0.75, 95% CI: 0.64-0.87) were associated with reduced odds of severe ROP. Conclusion: The incidence of severe ROP in very preterm infants in China was high compared to the developed countries, and intravitreal anti-VEGF injection was the preferred treatment for severe ROP.

Indexed as

anti-VEGF injectionincidenceretinopathy of prematurityrisk factortreatment

Identifiers

PMID41048932
PMCPMC12489369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.